Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANEMIAR

Financiado

Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia b...

Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity. Compared to DNA-based gene therapy, mRNA has significant advantages includi... ver más

30/09/2026

FUNDACIÓN PARA LA...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-15

HORIZON-HLTH-2022-DISEASE-06-04-two-stage: Development of new effective therap... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100%

4 Participantes

FUNDACIÓN PARA LA FORMACIÓN...

907.25K€ | Lider

SMS

87.50K€ | Participante

MERCURNA BV

914.73K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2017-127 TERAPIA GENICA BASADA EN HIPERTERMIA MAGNETICA LOCALIZADA PA... 96K€ Cerrado

RTI2018-097609-B-C22 SISTEMAS MULTIFUNCIONALES PARA QUIMIOTERAPIA/TERAPIA GENICA... 57K€ Cerrado

PCIN-2017-060 TERAPIA GENICA BASADA EN HIPERTERMIA MAGNETICA LOCALIZADA PA... 122K€ Cerrado

NANO-ENGINE A revolutionary cell programming platform based on the targe... 3M€ Cerrado

CARTHAGO Cartilaginous tissue regeneration by non viral gene therapy... 4M€ Cerrado

SAF2014-56763-R DISEÑO Y EVALUACION DE AGENTES TERAPEUTICOS Y SENSORES BASAD... 97K€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2023-03-15
Fecha Fin: 2026-09-30

Líder del proyecto

FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Presupuesto del proyecto 3M€

Descripción del proyecto Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity. Compared to DNA-based gene therapy, mRNA has significant advantages including higher intrinsic safety (non-integrating), lower cost of development, and less stringent regulatory requirements for clinical approval. In the NANEMIAR project, we take advantage of these benefits to kill 2 birds with 1 stone: first, we develop a first-of-its-kind nanomedicine for congenital anemia, a group of rare, inherited blood disorders characterized by ineffective red blood cell production. Our proposed bone marrow-targeted mRNA-based therapy contributes to the first Horizon Europe strategic plan (2021-2024) for new and advanced therapies for non-communicable diseases and is expected to be a vast improvement over current treatment options in terms of efficacy and safety. Second, we provide critical knowledge on targeted non-viral polynucleotide delivery, with a platform that can be exploited for next-generation cell and gene therapy in a broader context. To achieve this, our consortium combines the unique cell-targeting and mRNA knowledge from the Dutch Biotech Mercurna with two excellent research partners (from Spain and France) who have demonstrated expertise in the field of anemia. By focusing on the well-recognized rare disease model, beta-thalassemia, and combining an established mouse model, patient material, and previous drug development experience we build a convincing case to treat congenital anemia.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores